In a total of 26 ibezapolstat-treated patients in Phases 2a and 2b, the Clinical Cure rate is 96% Meets protocol primary objective of assessing the primary.
A novel antibiotic therapy for Clostridioides difficile infection, currently dubbed CRS3123, has demonstrated narrower selectivity and reduced bacterial derangement in the gut compared with other antibiotics.
Testing stool samples for C difficile exotoxins A and B is frequently used to diagnose a C difficile infection, but clinicians need a greater understanding of what the results mean.
Peggy Lillis Foundation and Ferring Pharmaceuticals Partner to Support Patients with C. difficile Infection
Share Article
Peggy Lillis Foundation for C. diff Education & Advocacy (PLF), the leading patient organization combating C. difficile infections (CDI), partners with Ferring Pharmaceuticals through a new sponsorship to help fund new and existing patient advocacy initiatives. Joining forces, PLF and Ferring are eager to continue helping people living with CDI and their loved ones.
PLF Stacked Logo
We are incredibly grateful for Ferring’s generous sponsorship as well as its ongoing partnership in the fight against CDI. BROOKLYN, N.Y. (PRWEB) March 11, 2021 Peggy Lillis Foundation for C. diff Education & Advocacy (PLF), the leading patient organization combating C. difficile infections (CDI), partners with Ferring Pharmaceuticals through a new sponsorship to help fund new and existing patient advocacy init